Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

Eli Lilly continues to show strong GLP-1 momentum, with Mounjaro sales up 125% and Zepbound sales up 80% in Q1 2026, while Mounjaro sales still grew 10% in India despite low-cost Wegovy generics. The article also highlights a new GLP-1 drug in development that may be more effective than current offerings, supporting Lilly's competitive position versus Novo Nordisk. Morgan Stanley estimates Lilly controls slightly over 50% of the international GLP-1 market, though valuation remains elevated at roughly 38x earnings.

Analysis

The market is still framing GLP-1 as a U.S. share-shift story, but the more durable edge is turning into an international execution test. Lilly’s ability to hold pricing and grow volume in a market where a branded rival lost patent exclusivity suggests the franchise is becoming less dependent on U.S. reimbursement optics and more on perceived efficacy leadership. That matters because the first-order revenue upside is only part of the trade; the second-order effect is that a stronger ex-U.S. brand extends the earnings duration and compresses the probability of a near-term share war causing multiple compression.

The bigger underappreciated catalyst is that Novo’s pill does not fully solve the efficacy gap, while Lilly’s pipeline may widen it further. If next-gen data are even modestly better than current injectables, the market will likely re-rate Lilly as a platform company rather than a single-product obesity trade, which supports a higher terminal multiple despite today’s valuation. By contrast, Novo’s near-term wedge looks tactical rather than structural, so any relief rally in NVO is more likely to fade unless it can show comparable outcome durability in real-world use.

The contrarian read is that the most bullish signal is not U.S. demand but the fact that lower-priced alternatives are not fully displacing the incumbent in a price-sensitive market. That implies demand is still efficacy-elastic, not price-elastic, which is favorable for premium biologics and unfavorable for generic encroachment. The main risk is a faster-than-expected normalization in obesity script growth over the next 2-3 quarters if payers tighten access or if international adoption proves narrower than current estimates.

Key Decisions for Investors

• Long LLY vs short NVO as a 3-6 month relative-value trade: thesis is Lilly’s efficacy advantage and ex-U.S. resilience will sustain a premium multiple; stop if NVO demonstrates comparable real-world uptake or Lilly’s next-gen data disappoint.
• Buy LLY call spreads 6-12 months out to express upside to pipeline re-rating while limiting valuation risk; best payoff if the next GLP-1 readout confirms superiority and the stock re-rates toward its historical premium band.
• Fade any NVO bounce into strength via a short or put spread, with a 1-2 quarter horizon: the market may be overestimating the pill as a durable share recapture lever if efficacy remains the key buying criterion.
• For lower-volatility exposure, pair long LLY / short MS or another high-quality large-cap financials name on the idea that Morgan Stanley’s channel-check optimism could keep supporting LLY estimates while downside in MS is limited to sentiment noise.
• Reduce willingness to sell LLY on valuation alone until there is evidence of slowing ex-U.S. volume; the current multiple is high but not extreme relative to its own history if the international share gains prove sticky.